ArticleMolecular cancer therapeutics2008
Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.
Article in Molecular cancer therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology Group.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Biomechanical Aspects in Bone Tumor Engineering.Tissue engineering. Part B, Reviews · 2024Review
- Investigation of the activity of a novel tropolone in osteosarcoma.Drug development research · 2024Article
- Osteosarcoma and Metastasis Associated Bone Degradation-A Tale of Osteoclast and Malignant Cell Cooperativity.International journal of molecular sciences · 2021Review
- Osteosarcoma and Metastasis.Frontiers in oncology · 2021Review
- RANK-RANKL signalling in cancer.Bioscience reports · 2016Review
- Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.Stem cells international · 2016Review
- RANK and RANK ligand expression in primary human osteosarcoma.Journal of bone oncology · 2015Article
- Bone microenvironment signals in osteosarcoma development.Cellular and molecular life sciences : CMLS · 2015Review
- Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma.Frontiers in oncology · 2015Review
- State-of-the-art approach for bone sarcomas.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2015Review
- Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma.Drug design, development and therapy · 2015Article
- Extracellular Membrane Vesicles Derived from 143B Osteosarcoma Cells Contain Pro-Osteoclastogenic Cargo: A Novel Communication Mechanism in Osteosarcoma Bone Microenvironment.Translational oncology · 2014Article
- Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis.PloS one · 2014Article
- Children's Oncology Group's 2013 blueprint for research: bone tumors.Pediatric blood & cancer · 2013Review
- Novel strategies for the treatment of chondrosarcomas: targeting integrins.BioMed research international · 2013Review
- Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences.Journal of bone oncology · 2012Review
- Bone sarcomas: from biology to targeted therapies.Sarcoma · 2012Article
- Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.Clinical & experimental metastasis · 2011Article
- Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence.PloS one · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most frequent primary bone tumor that develops mainly during youth, the median age of diagnosis being 18 years. Despite improvement in osteosarcoma treatment, survival rate is only 30% after 5 years for patients with pulmonary metastases at diagnosis. This warrants exploration of new therapeutic options. The anti-bone resorption molecule receptor activator of NF-kappaB (RANK) is very promising, as it may block the vicious cycle between bone resorption and tumor proliferation that takes place during tumor development in bone site. The cDNA encoding murine RANK-Fc (mRANK-Fc) was administered by gene transfer using an amphiphilic polymer in a mouse model of osteolytic osteosarcoma. Clinical and bone microarchitecture variables were assessed by radiography and micro-CT analyses. In vitro experiments were designed to determine the mechanism of action of RANK-Fc on tumor cell proliferation (XTT assays), apoptosis (caspase activation), cell cycle distribution (fluorescence-activated cell sorting analysis), or gene expression (reverse transcription-PCR). RANK-Fc was effective in preventing the formation of osteolytic lesions associated with osteosarcoma development and in reducing the tumor incidence, the local tumor growth, and the lung metastases dissemination leading to a 3.9-fold augmentation of mice survival 28 days after implantation. On the contrary, mRANK-Fc did not prevent the development of nonosseous tumor nodules, suggesting that bone environment is necessary for mRANK-Fc therapeutic efficacy. Furthermore, mRANK-Fc has no direct activity on osteosarcoma cells in vitro. mRANK-Fc exerts an indirect inhibitory effect on osteosarcoma progression through inhibition of bone resorption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.